Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dal-GenE trial of dalcetrapib after recent acute coronary syndrome in ADCY9 AA genotype patients
NL-OMON55786Phase 3Completed
- Sponsor
- DalCor Pharmaceuticals
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dalcetrapib in acute coronary syndrome (ACS) and atherosclerotic disease, sponsored by DalCor Pharmaceuticals. Started Sep 2016; status: completed.
02
Drugs
dalcetrapib
03
Conditions
acute coronary syndrome (ACS)atherosclerotic disease
Beyond the preview
Go deeper on NL-OMON55786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55786.